Complement Factor B: An Important Regulatory Factor for Protecting the Body's Immune System
The complement system is an essential component of the human innate immune system. It relies on the synergistic effects of multiple activation pathways to fend off exogenous invaders, eliminate damaged cells, and maintain the homeostasis of the internal bodily environment. Complement Factor B (CFB), a core component of the alternative complement activation pathway, serves as a critical link connecting upstream and downstream steps throughout the immune cascade reaction, and is also a key research focus in the fields of immunology, inflammation and associated diseases.
Under physiological conditions, circulating CFB can be specifically cleaved by Complement Factor D into two functional fragments: Ba and Bb. The Bb fragment binds to complexes to form C3 convertase, continuously driving the orderly progression of complement reactions. Relying on this mechanism, the alternative complement pathway can rapidly initiate immune responses without antibody involvement, efficiently eliminate pathogens such as bacteria, fungi and viruses, and simultaneously clear accumulated immune complexes as well as senescent and damaged cells in the body, forming the first line of immune defense of the organism. During tissue repair, local immune responses mediated by CFB also facilitate the clearance of lesion tissues, creating favorable conditions for organ and tissue regeneration.
Normal complement activation protects bodily health, whereas abnormal CFB expression and excessive pathway activation disrupt immune balance and induce various pathological injuries. In autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, overactivated complement systems continuously generate abundant inflammatory mediators that persistently attack self-tissues, exacerbating inflammatory responses and organ damage. In various renal lesions, abnormally accumulated CFB contributes to glomerular structural destruction, acting as a major driver of the onset and progression of proteinuria and renal dysfunction. Furthermore, CFB is deeply involved in ocular lesions and tumor microenvironment remodeling. Its expression level is closely correlated with disease progression and severity, offering novel directions for disease subtyping, prognosis assessment and the development of new drug targets.
In diverse basic research and drug development programs, accurate quantification of CFB concentrations in samples constitutes a core step for evaluating complement activation levels, elucidating disease pathogenesis, and assessing drug efficacy. Given that this protein is prone to degradation ex vivo and other complement components in biological samples may cause interference, detection methods are required to deliver high specificity and stability. Enzyme-Linked Immunosorbent Assay (ELISA) has become the predominant technique for CFB quantification due to its convenient operation, high sensitivity and compatibility with high-throughput sample testing.
Our company’s Complement Factor B ELISA Kit adopts a highly specific paired antibody strategy that precisely targets the protein of interest, minimizes cross-reactivity, and effectively reduces experimental background interference. The product has undergone repeated optimization with multiple types of biological samples, coupled with standardized reaction systems and washing protocols, resulting in excellent intra-assay and inter-assay coefficient of variation. The complete reagent kit is ready-to-use with streamlined, standardized operating procedures, compatible with mainstream laboratory microplate readers without the need for complex additional experimental setups. It delivers stable and accurate data support for basic mechanistic research, large-scale sample screening, and preclinical pharmacodynamic evaluation of anti-inflammatory and immunomodulatory drugs, empowering researchers to advance immunology research and accelerate the translation of relevant studies and innovative achievements.
Under physiological conditions, circulating CFB can be specifically cleaved by Complement Factor D into two functional fragments: Ba and Bb. The Bb fragment binds to complexes to form C3 convertase, continuously driving the orderly progression of complement reactions. Relying on this mechanism, the alternative complement pathway can rapidly initiate immune responses without antibody involvement, efficiently eliminate pathogens such as bacteria, fungi and viruses, and simultaneously clear accumulated immune complexes as well as senescent and damaged cells in the body, forming the first line of immune defense of the organism. During tissue repair, local immune responses mediated by CFB also facilitate the clearance of lesion tissues, creating favorable conditions for organ and tissue regeneration.
Normal complement activation protects bodily health, whereas abnormal CFB expression and excessive pathway activation disrupt immune balance and induce various pathological injuries. In autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, overactivated complement systems continuously generate abundant inflammatory mediators that persistently attack self-tissues, exacerbating inflammatory responses and organ damage. In various renal lesions, abnormally accumulated CFB contributes to glomerular structural destruction, acting as a major driver of the onset and progression of proteinuria and renal dysfunction. Furthermore, CFB is deeply involved in ocular lesions and tumor microenvironment remodeling. Its expression level is closely correlated with disease progression and severity, offering novel directions for disease subtyping, prognosis assessment and the development of new drug targets.
In diverse basic research and drug development programs, accurate quantification of CFB concentrations in samples constitutes a core step for evaluating complement activation levels, elucidating disease pathogenesis, and assessing drug efficacy. Given that this protein is prone to degradation ex vivo and other complement components in biological samples may cause interference, detection methods are required to deliver high specificity and stability. Enzyme-Linked Immunosorbent Assay (ELISA) has become the predominant technique for CFB quantification due to its convenient operation, high sensitivity and compatibility with high-throughput sample testing.
Our company’s Complement Factor B ELISA Kit adopts a highly specific paired antibody strategy that precisely targets the protein of interest, minimizes cross-reactivity, and effectively reduces experimental background interference. The product has undergone repeated optimization with multiple types of biological samples, coupled with standardized reaction systems and washing protocols, resulting in excellent intra-assay and inter-assay coefficient of variation. The complete reagent kit is ready-to-use with streamlined, standardized operating procedures, compatible with mainstream laboratory microplate readers without the need for complex additional experimental setups. It delivers stable and accurate data support for basic mechanistic research, large-scale sample screening, and preclinical pharmacodynamic evaluation of anti-inflammatory and immunomodulatory drugs, empowering researchers to advance immunology research and accelerate the translation of relevant studies and innovative achievements.
